Imaging cancer using PET - the effect of the bifunctional chelator on the biodistribution of a 64Cu-labeled antibody

Nuclear Medicine and Biology

Volumn 38, Issue 1, 2011, Pages 29-38

  Dearling, Jason L J ^a,b   Voss, Stephan D ^a,b   Dunning, Patricia ^a   Snay, Erin ^a   Fahey, Frederic ^a,b   Smith, Suzanne V ^c   Huston, James S ^d,e   Meares, Claude F ^f   Treves, S Ted ^a,b   Packard, Alan B ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION   (Australia)

^d EMD Serono Research Center   (United States)

^e BOSTON BIOMEDICAL RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antibody biodistribution; Copper 64; NOTA; Protein radiolabeling; SarAr

Indexed keywords

CYCLOSPORIN A [4 LEUCINE]; GD2 ANTIBODY 1 N (4 AMINOBENZYL) 3,6,10,13,16,19 HEXAAZABICYCLO[6.6.6]EICOSANE 1,8 DIAMINE CU 64; GD2 ANTIBODY 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID CU 64; GD2 ANTIBODY 2 (4 AMINOBENZYL) 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID CU 64; GD2 ANTIBODY 2 (AMINOBENZYL) 1,4,7 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID CU 64; GD2 ANTIBODY 6 [4 (BROMOACETAMIDO)BENZYL] 1,4,8,11 TETRAAZACYCLOTETRADECANE N,N',N'',N''' TETRAACETIC ACID CU 64; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; BLOOD; COMPLEX FORMATION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG SCREENING; DRUG STABILITY; DRUG TARGETING; DRUG TUMOR LEVEL; DRUG UPTAKE; EX VIVO STUDY; FEMALE; IMAGE ANALYSIS; KIDNEY; LIVER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RADIOIMMUNOLOGY; SPLEEN; THERMODYNAMICS; TISSUE LEVEL; TUMOR VOLUME;

ANILINE COMPOUNDS; ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CHELATING AGENTS; COPPER RADIOISOTOPES; CROSS-LINKING REAGENTS; FEMALE; HETEROCYCLIC COMPOUNDS; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; IMMUNOCONJUGATES; MELANOMA; MICE; POSITRON-EMISSION TOMOGRAPHY;

EID: 78650990169     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2010.07.003     Document Type: Article

References (33)

1. Blower P.J., Lewis J.S., Zweit J. Copper radionuclides and radiopharmaceuticals in nuclear medicine. Nucl Med Biol 1996, 23(8):957-980.
2. Moi M.K., Meares C.F., McCall M.J., Cole W.C., DeNardo S.J. Copper chelates as probes of biological systems: stable copper complexes with a macrocyclic bifunctional chelating agent. Anal Biochem 1985, 148(1):249-253.
3. Bass L., Wang M., Welch M.J., Anderson C.J. In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver. Bioconjug Chem 2000, 11(4):527-532.
4. Mirick G.R., O'Donnell R.T., DeNardo S.J., Shen S., Meares C.F., DeNardo G.L. Transfer of copper from a chelated 67Cu-antibody conjugate to ceruloplasmin in lymphoma patients. Nucl Med Biol 1999, 26(7):841-845.
5. Smith S.V. Molecular imaging with copper-64. J Inorg Biochem 2004, 98(11):1874-1901.
6. Di Bartolo N., Sargeson A.M., Smith S.V. New 64Cu PET imaging agents for personalised medicine and drug development using the hexa-aza cage, SarAr. Org Biomol Chem 2006, 4(17):3350-3357.
7. Voss S.D., Smith S.V., DiBartolo N., McIntosh L.J., Cyr E.M., Bonab A.A., et al. Positron emission tomography (PET) imaging of neuroblastoma and melanoma with 64Cu-SarAr immunoconjugates. Proc Natl Acad Sci U S A 2007, 104(44):17489-17493.
8. Bevilacqua A., Gelb R.I., Hebard W.B., Zompa L.J. Equilibrium and thermodynamic study of the aqueous complexation of 1,4,7-triazacyclononane-N,N′,N′-triacetic acid with protons, alkaline-earth-metal cations, and copper (II). Inorg Chem 1987, 26:2699-2706.
9. Delgado R., Sun Y., Motekaitis R.J., Martell A.E. Stabilities of divalent and trivalent metal ion complexes of macrocyclic triazatriacetic acids. Inorg Chem 1993, 32:3320-3326.
10. Clarke E.T., Martell A. Stabilities of the alkaline earth and divalent transition metal complexes of the tetraazamacrocyclic tetraacetic acid ligands. Inorganica Chimica Acta 1991, 190:27-36.
11. Delgado R., da Silva J.J. Metal complexes of cyclic tetra-azatetra-acetic acids. Talanta 1982, 29(10):815-822.
12. Di Bartolo N.M., Sargeson A.M., Donlevy T.M., Smith S.V. Synthesis of a new cage ligand, SarAr, and its complexation with selected transition metal ions for use in radioimaging. J Chem Soc, Dalton Trans 2001, 2303-2309.
13. Moran J.K., Greiner D.P., Meares C.F. Improved synthesis of 6-[p-(bromoacetamido)benzyl]-1,4,8,11-tetraazacyclotetradecane-N,N′,N′,N′′-tetraacetic acid and development of a thin-layer assay for thiol-reactive bifunctional chelating agents. Bioconjug Chem 1995, 6(3):296-301.
14. Gillies S.D., Lo K.M., Wesolowski J. High-level expression of chimeric antibodies using adapted cDNA variable region cassettes. J Immunol Methods 1989, 125(1-2):191-202.
15. Lewis M.R., Kao J.Y., Anderson A.L., Shively J.E., Raubitshek A. An improved method for conjugating monoclonal antibodies with N-hydroxysulfosuccinimidyl DOTA. Bioconjug Chem 2001, 12(2):320-324.
16. McCall M.J., Diril H., Meares C.F. Simplified method for conjugating macrocyclic bifunctional chelating agents to antibodies via 2-iminothiolane. Bioconjug Chem 1990, 1(3):222-226.
17. Meares C.F., McCall M.J., Reardon D.T., Goodwin D.A., Diamanti C.I., McTigue M. Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions. Anal Biochem 1984, 142(1):68-78.
18. Mueller B.M., Reisfeld R.A., Gillies S.D. Serum half-life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2. Proc Natl Acad Sci U S A 1990, 87(15):5702-5705.
19. Grunberg J., Novak-Hofer I., Honer M., Zimmermann K., Knogler K., Blauenstein P., et al. In vivo evaluation of 177Lu- and 67/64Cu-labeled recombinant fragments of antibody chCE7 for radioimmunotherapy and PET imaging of L1-CAM-positive tumors. Clin Cancer Res 2005, 11(14):5112-5120.
20. Zimmermann K., Grunberg J., Honer M., Ametamey S., Schubiger P.A., Novak-Hofer I. Targeting of renal carcinoma with 67/64Cu-labeled anti-L1-CAM antibody chCE7: selection of copper ligands and PET imaging. Nucl Med Biol 2003, 30(4):417-427.
21. Kukis D.L., DeNardo G.L., DeNardo S.J., Mirick G.R., Miers L.A., Greiner D.P., et al. Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates. Cancer Res 1995, 55(4):878-884.
22. Hagan P.L., Halpern S.E., Dillman R.O., Shawler D.L., Johnson D.E., Chen A., et al. Tumor size: effect on monoclonal antibody uptake in tumor models. J Nucl Med 1986, 27(3):422-427.
23. Pedley R.B., Boden J., Keep P.A., Harwood P.J., Green A.J., Rogers G.T. Relationship between tumour size and uptake of radiolabelled anti-CEA in a colon tumour xenograft. Eur J Nucl Med 1987, 13(4):197-202.
24. Chen P., Cameron R., Wang J., Vallis K.A., Reilly R.M. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts. J Nucl Med 2003, 44(9):1469-1478.
25. Jones-Wilson T.M., Deal K.A., Anderson C.J., McCarthy D.W., Kovacs Z., Motekaitis R.J., et al. The in vivo behavior of copper-64-labeled azamacrocyclic complexes. Nucl Med Biol 1998, 25(6):523-530.
26. Rogers B.E., Anderson C.J., Connett J.M., Guo L.W., Edwards W.B., Sherman E.L., et al. Comparison of four bifunctional chelates for radiolabeling monoclonal antibodies with copper radioisotopes: biodistribution and metabolism. Bioconjug Chem 1996, 7(4):511-522.
27. Kukis D.L., Diril H., Greiner D.P., DeNardo S.J., DeNardo G.L., Salako Q.A., et al. A comparative study of copper-67 radiolabeling and kinetic stabilities of antibody-macrocycle chelate conjugates. Cancer 1994, 73(3 Suppl):779-786.
28. Cole W.C., DeNardo S.W., Meares C.F., McCall M.J., DeNardo G.L., Epstein A.L., et al. Serum stability of 67Cu chelates: comparison with 111In and 57Co. Int J Rad Appl Instrum B 1986, 13(4):363-368.
29. Prasanphanich A.F., Retzloff L., Lane S.R., Nanda P.K., Sieckman G.L., Rold T.L., et al. In vitro and in vivo analysis of [(64)Cu-NO2A-8-Aoc-BBN(7-14)NH(2)]: a site-directed radiopharmaceutical for positron-emission tomography imaging of T-47D human breast cancer tumors. Nucl Med Biol 2009, 36(2):171-181.
30. Prasanphanich A.F., Nanda P.K., Rold T.L., Ma L., Lewis M.R., Garrison J.C., et al. [64Cu-NOTA-8-Aoc-BBN(7-14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues. Proc Natl Acad Sci U S A 2007, 104(30):12462-12467.
31. Margerum D., Cayley G.R., Weatherburn D.C., Pagenkopf G.K. Kinetics and mechanisms of complex formation and ligand exchange. Coordination Chemistry Volume 2, ACS Monograph 174 1978, 1-194. American Chemical Society, Washington, DC. A. Martell (Ed.).
32. Ringbom A. Complexation in analytical chemistry: a guide for the critical selection of analytical methods based on complexation reactions. Chemical analysis 1963, 360. Interscience Publishers, New York. P. Elving, I. Kolthoff (Eds.).
33. Pippin C.G., Kumar K., Mirzadeh S., Gansow O.A. Kinetics of the isotopic exchange between copper(II) and copper (II) 1,4,7-triazacyclononane-N,N′,N′ triacetate. J Lab Comp Radiopharm 1991, 30:227-228.